source
- STAT+: Supreme Court to hear case about ‘skinny labeling’ and generic accessThe Supreme Court Wednesday will hear oral arguments about a simmering controversy over so-called skinny labels, with implications for the availability of generics.STAT · 3mo ago↗ source
- FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ resultsTavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.BioPharma Dive · 3mo ago↗ source
- STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data neededEli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news todaySTAT · 3mo ago